Essential Thrombocythemia - Pipeline Review, H1 2020

April 2020 | 115 pages | ID: E584A1C8AD2EN
Global Markets Direct

Abstracts

Essential Thrombocythemia - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Essential Thrombocythemia - Pipeline Review, H1 2020, provides an overview of the Essential Thrombocythemia (Oncology) pipeline landscape.

Essential thrombocythemia is a chronic myeloproliferative neoplasm in which cells in the bone marrow that produce the blood cells develop and function abnormally. In essential thrombocythemia, there is mainly an overproduction of platelet forming cells (megakaryocytes) in the marrow. Symptoms of essential thrombocythemia include headache, dizziness, weakness or numbness on one side of the body, slurred speech and transient ischemic attacks.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Essential Thrombocythemia - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Essential Thrombocythemia (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Essential Thrombocythemia (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Essential Thrombocythemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II and Phase I stages are 2, 6 and 6 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

Essential Thrombocythemia (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Essential Thrombocythemia (Oncology).
• The pipeline guide reviews pipeline therapeutics for Essential Thrombocythemia (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Essential Thrombocythemia (Oncology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Essential Thrombocythemia (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Essential Thrombocythemia (Oncology)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Essential Thrombocythemia (Oncology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Essential Thrombocythemia (Oncology) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Essential Thrombocythemia - Overview
Essential Thrombocythemia - Therapeutics Development
Essential Thrombocythemia - Therapeutics Assessment
Essential Thrombocythemia - Companies Involved in Therapeutics Development
Essential Thrombocythemia - Drug Profiles
Essential Thrombocythemia - Dormant Projects
Essential Thrombocythemia - Discontinued Products
Essential Thrombocythemia - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Essential Thrombocythemia, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Essential Thrombocythemia - Pipeline by AbbVie Inc, H1 2020
Essential Thrombocythemia - Pipeline by F. Hoffmann-La Roche Ltd, H1 2020
Essential Thrombocythemia - Pipeline by Imago BioSciences Inc, H1 2020
Essential Thrombocythemia - Pipeline by Incyte Corp, H1 2020
Essential Thrombocythemia - Pipeline by IO Biotech ApS, H1 2020
Essential Thrombocythemia - Pipeline by Italfarmaco SpA, H1 2020
Essential Thrombocythemia - Pipeline by MEI Pharma Inc, H1 2020
Essential Thrombocythemia - Pipeline by Millennium Pharmaceuticals Inc, H1 2020
Essential Thrombocythemia - Pipeline by PharmaEssentia Corp, H1 2020
Essential Thrombocythemia - Pipeline by Sino Biopharmaceutical Ltd, H1 2020
Essential Thrombocythemia - Dormant Projects, H1 2020
Essential Thrombocythemia - Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Essential Thrombocythemia, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020

COMPANIES MENTIONED

AbbVie Inc
F. Hoffmann-La Roche Ltd
Imago BioSciences Inc
Incyte Corp
IO Biotech ApS
Italfarmaco SpA
MEI Pharma Inc
Millennium Pharmaceuticals Inc
PharmaEssentia Corp
Sino Biopharmaceutical Ltd